Download PDF Tivozanib Data Also Presented at Annual Chemotherapy Foundation Symposium CAMBRIDGE, Mass., Nov 10, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company’s lead product candidate, tivozanib, a highly
Category: Press Release
AVEO Reports Third Quarter 2010 Financial Results and Recent Developments
Download PDF Current Financial Position Supports Expanding and Accelerating Clinical Development Plans for Tivozanib CAMBRIDGE, Mass., Nov 04, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced updated financial guidance and third quarter financial results, as well as recent developments. “During the
AVEO Pharmaceuticals’ Tivozanib Recognized as One of Windhover’s 2011 Top 10 Oncology Projects to Watch
Download PDF AVEO to Present at Windhover’s Annual Therapeutic Area Partnerships Meeting CAMBRIDGE, Mass., Nov 03, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that its lead product candidate, tivozanib, has been selected as one of Windhover’s “2011 Top 10 Oncology
AVEO Pharmaceuticals Announces $61 Million Private Placement
Download PDF Proceeds to Fund Expanding and Accelerating Clinical Development Plans for Tivozanib CAMBRIDGE, Mass., Oct 29, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the execution of a securities purchase agreement with a select group of institutional and accredited investors
AVEO Pharmaceuticals, Inc. Announces Timing for Third Quarter 2010 Financial Results, Webcast and Conference Call
Download PDF CAMBRIDGE, Mass., Oct 21, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that financial results for the company’s third quarter ended September 30, 2010 will be released before the market opens on Thursday, November 4, 2010. The AVEO management
AVEO Pharmaceuticals’ Tivozanib Clinical Data Featured at ESMO
Download PDF CAMBRIDGE, Mass. & MILAN, Oct 11, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that previously reported results from its Phase 2 study evaluating tivozanib for the treatment of advanced renal cell carcinoma (RCC) were presented at the 35th European
AVEO Pharmaceuticals’ Tivozanib Featured at Ninth International Kidney Cancer Symposium
Download PDF Tivozanib Clinical Data and Pipeline Overview Presented CAMBRIDGE, Mass., Oct 01, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that previously reported results from its Phase 2 study evaluating tivozanib for the treatment of advanced renal cell carcinoma (RCC)
AVEO Pharmaceuticals Regains Worldwide Rights to Develop and Commercialize Anti-HGF Antibody Candidate AV-299
Download PDF CAMBRIDGE, Mass., Sep 30, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that AVEO has regained worldwide rights from Merck (through its subsidiary, Schering Corporation) to develop and commercialize AV-299 (also known as SCH 900105), its anti-hepatocyte growth factor
AVEO Pharmaceuticals, Inc. to Present at Upcoming Oncology Medical Meetings and Investment Conference
Download PDF CAMBRIDGE, Mass., Sep 28, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the company will have a presence at two upcoming oncology medical meetings and Citi’s 5th Annual Biotech Day investment conference. Data from AVEO’s tivozanib clinical development program
AVEO Pharmaceuticals, Inc. Appoints Michael P. Bailey to the Newly Created Position of Chief Commercial Officer
Download PDF Company Enhances Leadership Team and Prepares for Forward Integration CAMBRIDGE, Mass., Sep 13, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the appointment of Michael P. Bailey to the newly created role of chief commercial officer, as well as